AstraZeneca axes jobs, closes plants
Anglo-Swedish drug major AstraZeneca has revealed that it will close three manufacturing plants and shed around 1,400 jobs by 2013, as well as invest more for growth in the Asia Pacific markets, as part of it ongoing program to improve efficiency across the business. This is in addition to 7,600 redundancies announced in 2007.
The company will exit three sites - Porrino in Spain, Desekbergen in Belgium and Umea in Sweden - and there will be jobs affected in Macclesfield, UK and Sodertalje, Sweden. However, the UK-headquartered drugmaker says it will invest further in its Wuxi plant in China to support the company's growth, with the addition of packaging and formulation capabilities to enable this facility to become an important center for the Asia Pacific region, complementing those in Europe and Latin America. Actual investment figures were not disclosed.
Warns on full-year guidance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze